NGNE
Neurogene Inc.
Biotechnology
Market Cap$488M
5Y Perf.-87.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
NGNE vs RCKT
Revenue, margins, valuation, and 5-year total return — side by side.
RCKT
Rocket Pharmaceuticals, Inc.
Biotechnology
Market Cap$398M
5Y Perf.-80.5%
NGNE vs RCKT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | NGNE | RCKT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $488M | $398M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-90M | $-223M |
| Total Debt | $10M | $25M |
| Cash & Equiv. | $104M | $78M |
NGNE vs RCKT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NGNE
RCKT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Neurogene Inc. (NGNE) | 100 | 12.8 | -87.2% |
| Rocket Pharmaceutic… (RCKT) | 100 | 19.5 | -80.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NGNE vs RCKT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NGNE and RCKT are tied at the top with 2 categories each — the right choice depends on your priorities. Rocket Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
NGNE
Neurogene Inc.
The Long-Run Compounder
NGNE has the current edge in this matchup, primarily because of its strength in long-term compounding and sleep-well-at-night.
- -79.8% 10Y total return vs RCKT's -91.3%
- Lower volatility, beta 2.16, Low D/E 3.7%, current ratio 16.56x
- +125.5% vs RCKT's -45.2%
Best for: long-term compounding and sleep-well-at-night
RCKT
Rocket Pharmaceuticals, Inc.
The Income Pick
RCKT is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.31
- EPS growth 26.4%
- Beta 1.31, current ratio 6.38x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RCKT | 10.5% revenue growth vs NGNE's -100.0% |
| Stability / Safety | RCKT | Beta 1.31 vs NGNE's 2.16 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NGNE | +125.5% vs RCKT's -45.2% |
| Efficiency (ROA) | NGNE | -30.4% ROA vs RCKT's -67.5%, ROIC -43.3% vs -63.2% |
NGNE vs RCKT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
NGNE vs RCKT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNGNELAGGINGRCKT
RCKTRocket Pharmaceutical…
1leads
NGNENeurogene Inc.
2leads
6 Total Categories
CATEGORYLEADERvs RCKTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RCKT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NGNE8/8
Total Returns1Y, 3Y, 5Y total returns with dividends
NGNE6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RCKT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
NGNE and RCKT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | NGNENeurogene Inc. | RCKTRocket Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$100M | -$232M |
| Net IncomeAfter-tax profit | -$90M | -$223M |
| Free Cash FlowCash after capex | -$78M | -$190M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -22.1% | +38.7% |
RCKT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — NGNE and RCKT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | NGNENeurogene Inc. | RCKTRocket Pharmaceut… |
|---|---|---|
| Market CapShares × price | $488M | $398M |
| Enterprise ValueMkt cap + debt − cash | $394M | $345M |
| Trailing P/EPrice ÷ TTM EPS | -7.37x | -1.83x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 2.50x | 1.47x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — NGNE and RCKT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
NGNE leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
NGNE delivers a -33.0% return on equity — every $100 of shareholder capital generates $-33 in annual profit, vs $-80 for RCKT. NGNE carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to RCKT's 0.09x. On the Piotroski fundamental quality scale (0–9), NGNE scores 2/9 vs RCKT's 1/9, reflecting mixed financial health.
| Metric | NGNENeurogene Inc. | RCKTRocket Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -33.0% | -80.5% |
| ROA (TTM)Return on assets | -30.4% | -67.5% |
| ROICReturn on invested capital | -43.3% | -63.2% |
| ROCEReturn on capital employed | -34.8% | -58.9% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 1 |
| Debt / EquityFinancial leverage | 0.04x | 0.09x |
| Net DebtTotal debt minus cash | -$94M | -$53M |
| Cash & Equiv.Liquid assets | $104M | $78M |
| Total DebtShort + long-term debt | $10M | $25M |
| Interest CoverageEBIT ÷ Interest expense | -18628.20x | — |
NGNE leads this category, winning 8 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
NGNE leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NGNE five years ago would be worth $1,350 today (with dividends reinvested), compared to $838 for RCKT. Over the past 12 months, NGNE leads with a +125.5% total return vs RCKT's -45.2%. The 3-year compound annual growth rate (CAGR) favors NGNE at 21.1% vs RCKT's -44.4% — a key indicator of consistent wealth creation.
| Metric | NGNENeurogene Inc. | RCKTRocket Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | +55.1% | +6.1% |
| 1-Year ReturnPast 12 months | +125.5% | -45.2% |
| 3-Year ReturnCumulative with dividends | +77.6% | -82.8% |
| 5-Year ReturnCumulative with dividends | -86.5% | -91.6% |
| 10-Year ReturnCumulative with dividends | -79.8% | -91.3% |
| CAGR (3Y)Annualised 3-year return | +21.1% | -44.4% |
NGNE leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — NGNE and RCKT each lead in 1 of 2 comparable metrics.
Risk & Volatility
RCKT is the less volatile stock with a 1.31 beta — it tends to amplify market swings less than NGNE's 2.16 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NGNE currently trades 83.9% from its 52-week high vs RCKT's 49.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NGNENeurogene Inc. | RCKTRocket Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.16x | 1.31x |
| 52-Week HighHighest price in past year | $37.27 | $7.39 |
| 52-Week LowLowest price in past year | $12.97 | $2.19 |
| % of 52W HighCurrent price vs 52-week peak | +83.9% | +49.7% |
| RSI (14)Momentum oscillator 0–100 | 75.4 | 54.4 |
| Avg Volume (50D)Average daily shares traded | 195K | 3.5M |
Evenly matched — NGNE and RCKT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates NGNE as "Buy" and RCKT as "Buy". Consensus price targets imply 120.7% upside for NGNE (target: $69) vs 36.2% for RCKT (target: $5).
| Metric | NGNENeurogene Inc. | RCKTRocket Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $69.00 | $5.00 |
| # AnalystsCovering analysts | 6 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NGNE leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). RCKT leads in 1 (Income & Cash Flow). 2 tied.
Best OverallNeurogene Inc. (NGNE)Leads 2 of 6 categories
Loading custom metrics...
NGNE vs RCKT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is NGNE or RCKT a better buy right now?
Analysts rate Neurogene Inc.
(NGNE) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — NGNE or RCKT?
Over the past 5 years, Neurogene Inc.
(NGNE) delivered a total return of -86. 5%, compared to -91. 6% for Rocket Pharmaceuticals, Inc. (RCKT). Over 10 years, the gap is even starker: NGNE returned -79. 8% versus RCKT's -91. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — NGNE or RCKT?
By beta (market sensitivity over 5 years), Rocket Pharmaceuticals, Inc.
(RCKT) is the lower-risk stock at 1. 31β versus Neurogene Inc. 's 2. 16β — meaning NGNE is approximately 65% more volatile than RCKT relative to the S&P 500. On balance sheet safety, Neurogene Inc. (NGNE) carries a lower debt/equity ratio of 4% versus 9% for Rocket Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — NGNE or RCKT?
On earnings-per-share growth, the picture is similar: Rocket Pharmaceuticals, Inc.
grew EPS 26. 4% year-over-year, compared to 0. 9% for Neurogene Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — NGNE or RCKT?
Neurogene Inc.
(NGNE) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Rocket Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NGNE leads at 0. 0% versus 0. 0% for RCKT. At the gross margin level — before operating expenses — NGNE leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — NGNE or RCKT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is NGNE or RCKT better for a retirement portfolio?
For long-horizon retirement investors, Rocket Pharmaceuticals, Inc.
(RCKT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Neurogene Inc. (NGNE) carries a higher beta of 2. 16 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RCKT: -91. 3%, NGNE: -79. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between NGNE and RCKT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.